[go: up one dir, main page]

WO2008105392A1 - 3-amino-2-indolylbutyrolactam derivative, process for production of the same, and pharmaceutical agent comprising the same as active ingredient - Google Patents

3-amino-2-indolylbutyrolactam derivative, process for production of the same, and pharmaceutical agent comprising the same as active ingredient Download PDF

Info

Publication number
WO2008105392A1
WO2008105392A1 PCT/JP2008/053255 JP2008053255W WO2008105392A1 WO 2008105392 A1 WO2008105392 A1 WO 2008105392A1 JP 2008053255 W JP2008053255 W JP 2008053255W WO 2008105392 A1 WO2008105392 A1 WO 2008105392A1
Authority
WO
WIPO (PCT)
Prior art keywords
same
indolylbutyrolactam
derivative
amino
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/053255
Other languages
French (fr)
Japanese (ja)
Inventor
Mikiko Sodeoka
Tadashi Shimizu
Kosuke Dodo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIKEN
Original Assignee
RIKEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RIKEN filed Critical RIKEN
Publication of WO2008105392A1 publication Critical patent/WO2008105392A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Disclosed is a substance for inhibiting cell death, which is effective as a prophylactic or therapeutic agent for the progress of a condition of a disease whose of progress or exacerbation is associated with cell death. Specifically disclosed are: a compound represented by the general formula (1) and a pharmaceutically acceptable salt thereof; and a use application associated with a cell death-inhibiting activity of the compound.
PCT/JP2008/053255 2007-02-27 2008-02-26 3-amino-2-indolylbutyrolactam derivative, process for production of the same, and pharmaceutical agent comprising the same as active ingredient Ceased WO2008105392A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007047932A JP2008208086A (en) 2007-02-27 2007-02-27 3-Amino-2-indolylbutyrolactam derivative, process for producing the same, and medicament containing the same as an active ingredient
JP2007-047932 2007-02-27

Publications (1)

Publication Number Publication Date
WO2008105392A1 true WO2008105392A1 (en) 2008-09-04

Family

ID=39721223

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/053255 Ceased WO2008105392A1 (en) 2007-02-27 2008-02-26 3-amino-2-indolylbutyrolactam derivative, process for production of the same, and pharmaceutical agent comprising the same as active ingredient

Country Status (2)

Country Link
JP (1) JP2008208086A (en)
WO (1) WO2008105392A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100291533A1 (en) * 2008-01-04 2010-11-18 Soon Ha Kim Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042100A1 (en) * 1998-02-23 1999-08-26 Sagami Chemical Research Center Cell death inhibitors
WO2001013916A1 (en) * 1999-08-20 2001-03-01 Sagami Chemical Research Center Drugs inhibiting cell death

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042100A1 (en) * 1998-02-23 1999-08-26 Sagami Chemical Research Center Cell death inhibitors
WO2001013916A1 (en) * 1999-08-20 2001-03-01 Sagami Chemical Research Center Drugs inhibiting cell death

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DODO K. ET AL.: "Inhibition of hydrogen peroxide-induced necrotic cell death with 3-amino-2-indolylmaleimide derivatives", BIOORG. MED. CHEM. LETT., vol. 15, no. 12, 2005, pages 3114 - 3118, XP004915608 *

Also Published As

Publication number Publication date
JP2008208086A (en) 2008-09-11

Similar Documents

Publication Publication Date Title
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
WO2010122980A8 (en) NOVEL THYROID HORMONE β RECEPTOR AGONIST
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
NO20092033L (en) New connections
TW200637839A (en) 1-thio-d-glucitol derivatives
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
WO2010098600A3 (en) Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
MX2009006401A (en) Indazole derivatives as kinase inhibitors for the treatment of cancer.
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
UA97351C2 (en) Coumarin derivative having antitumor activity
WO2006098918A3 (en) Substituted gamma lactams as therapeutic agents
WO2009051119A1 (en) Pyrimidyl indoline compound
WO2007135527A3 (en) Benzimidazolyl compounds
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
WO2009030952A3 (en) Phenylcarboxamide derivatives as inhibitors and effectors of the hedgehog pathway
WO2009041663A1 (en) Agent for prevention and/or treatment of skin diseases
WO2011025982A3 (en) Tetracycline compounds
WO2009038412A3 (en) Beta-secretase inhibiting compounds
WO2011009714A3 (en) Benzoquinolizinium salt derivatives as anticancer agents
WO2009003719A3 (en) Indane-amine derivatives, their preparation and use as medicaments
WO2010132670A3 (en) Pentacycline compounds
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2007009721A3 (en) Indoline-substituted pyrazoline derivatives, their preparation and use as medicaments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711979

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08711979

Country of ref document: EP

Kind code of ref document: A1